



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

October 2024





© 2025 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to people living with HIV throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2022 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART



Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribers in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribers in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribers in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at birth

5. Appendix


- 5.1 Drug Names and Definitions



1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority

October 2024

N = 7746



Health Authority	Male	Female	All
FRASER	1630	505	2135
INTERIOR	500	114	614
NORTHERN	173	82	255
VANCOUVER COASTAL	3226	445	3671
VANCOUVER ISLAND	885	170	1055
	6414	1316	7730
	Unknown/not stated:		16
	Total:		7746

Definitions:

On antiretroviral therapy defined as being on treatment in the current month


Unknown/not stated defined as being on treatment in the current month, and city of residence unknown

Male & Female refer to Sex at birth





1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (October 2019 - October 2024)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (October 2019 - October 2024)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month






1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants (October 2019 - October 2024)






1.5 BC-CfE Enrolment: New Antiretroviral Participants (October 2019 - October 2024)






1.6 Percent Distribution of Active Participants by CD4 Count (October 2019 - October 2024)






1.7 Percent Distribution of Inactive Participants by CD4 Count
(October 2019 - October 2024)






1.8 Active and Inactive Participants (October 2019 - October 2024)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (October 2019 - October 2024)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (October 2019 - October 2024)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(October 2019 - October 2024)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (October 2019 - October 2024)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(October 2019 - October 2024)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (October 2019 - October 2024)






**1.15 Distribution of Participants on Non-Nucleosides
at the time of first start of ARV Therapy by INGREDIENT**

(October 2019 - October 2024)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (October 2019 - October 2024)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first ARV Therapy by INGREDIENT

(October 2019 - October 2024)






1.18 Baseline CD4 for Antiretroviral First Starts
(October 2019 - October 2024)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(October 2019 - October 2024)**






1.20 Cumulative Resistance Testing Results by Resistance Category (October 2019 - October 2024)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (October 2019 - October 2024)





2.1 Duration of ARV treatment in the Province of BC, 1987-2024 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	29	2	0	2	0		2	<40	3
1988	33	4	0	4	1	510	4	<40	4
1989	31	45	1	46	20	470	45	<40	3
1990	30	47	1	48	20	525	44	<40	3
1991	30	31	3	34	12	550	30	<40	3
1992	30	46	4	50	21	600	44	<40	3
1993	29	110	14	124	62	575	118	<40	3
1994	27	67	10	77	35	550	71	<40	3
1995	27	117	19	136	69	550	128	<40	3
1996	26	283	46	329	150	590	301	<40	3
1997	23	253	27	280	149	600	258	<40	3
1998	23	169	35	204	112	550	182	<40	3
1999	23	140	38	178	101	551	156	<40	3
2000	23	105	26	131	68	660	112	<40	3
2001	23	103	22	125	62	630	114	<40	3
2002	22	110	20	130	69	540	120	<40	3
2003	21	129	25	154	81	620	132	<40	3
2004	20	133	36	169	92	655	152	<40	3
2005	19	164	42	206	113	670	185	<40	3
2006	18	155	40	195	114	600	176	<40	3
2007	17	221	35	256	141	690	230	<40	3
2008	16	260	55	315	187	680	277	<40	3
2009	15	280	59	339	186	655	300	<40	3
2010	14	247	61	308	183	650	269	<40	3
2011	13	298	67	365	191	700	321	<40	3
2012	12	251	63	314	162	750	274	<40	3
2013	11	240	60	300	162	680	261	<40	3
2014	10	255	42	297	150	790	255	<40	3
2015	9	240	45	285	168	690	259	<40	3
2016	8	221	48	269	144	670	227	<40	3
2017	7	192	31	223	120	670	187	<40	3
2018	6	169	43	212	118	775	187	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.1 Duration of ARV treatment in the Province of BC, 1987-2024 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	5	204	42	246	156	720	220	<40	3
2020	4	156	52	208	131	760	179	<40	3
2021	3	182	33	215	120	655	185	<40	3
2022	2	241	48	289	186	700	262	<40	3
2023	1	273	62	335	221	600	315	<40	3
2024	0	266	62	328	264	570	318	<40	3
Total:		6409	1317	7726					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2023	7581	793	2051	<40	1320	650
FEB-2023	7521	807	1727	<40	1020	630
MAR-2023	7548	803	1974	<40	1215	640
APR-2023	7553	796	1761	<40	1084	630
MAY-2023	7592	786	1933	<40	1238	645
JUN-2023	7599	787	1841	<40	1098	640
JUL-2023	7577	806	1747	<40	1053	620
AUG-2023	7600	806	1814	<40	1041	630
SEP-2023	7609	797	1775	<40	1068	645
OCT-2023	7610	804	1887	<40	1152	620
NOV-2023	7612	798	1854	<40	1099	650
DEC-2023	7603	801	1549	<40	915	640
JAN-2024	7643	792	1973	<40	1171	650
FEB-2024	7647	784	1773	<40	1038	620
MAR-2024	7636	792	1681	<40	988	650
APR-2024	7671	786	1943	<40	1226	660
MAY-2024	7689	787	1880	<40	1075	660
JUN-2024	7690	786	1696	<40	1017	650
JUL-2024	7719	786	1808	<40	1017	610
AUG-2024	7715	782	1868	<40	1090	650
SEP-2024	7710	790	1660	<40	968	655
OCT-2024	7746	787	2012	<40	1087	650

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2023	734	276	63	<40	45	550
FEB-2023	787	230	66	<40	53	550
MAR-2023	756	242	78	<40	56	512
APR-2023	760	218	66	<40	47	560
MAY-2023	726	239	65	<40	48	430
JUN-2023	708	200	57	<40	39	460
JUL-2023	739	182	68	<40	50	565
AUG-2023	738	188	63	<40	40	595
SEP-2023	725	207	55	<40	41	540
OCT-2023	735	209	60	<40	46	625
NOV-2023	742	203	65	<40	46	515
DEC-2023	751	192	47	<40	35	473
JAN-2024	708	219	67	<40	49	520
FEB-2024	706	232	58	<40	41	560
MAR-2024	720	200	66	<40	46	565
APR-2024	702	228	67	<40	56	545
MAY-2024	700	217	57	<40	40	555
JUN-2024	714	194	59	<40	36	459
JUL-2024	705	196	54	<40	29	530
AUG-2024	715	198	69	<40	42	600
SEP-2024	715	186	52	<40	34	595
OCT-2024	703	199	60	<40	40	490

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrolment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2023	7550	734	20	10	193	143	40	14767
FEB-2023	7505	787	10	11	158	204	-45	14791
MAR-2023	7532	756	15	21	197	176	27	14825
APR-2023	7531	760	13	11	176	169	-1	14854
MAY-2023	7575	726	7	15	205	165	44	14898
JUN-2023	7577	708	14	17	168	165	3	14933
JUL-2023	7555	739	11	11	164	181	-22	14964
AUG-2023	7577	738	11	13	217	192	22	15009
SEP-2023	7579	725	14	5	179	163	2	15029
OCT-2023	7579	735	18	10	170	160	0	15060
NOV-2023	7578	742	18	9	182	171	-1	15096
DEC-2023	7574	751	14	13	169	169	-4	15129
JAN-2024	7614	708	16	11	204	158	40	15161
FEB-2024	7620	706	17	11	183	165	6	15193
MAR-2024	7616	720	12	14	182	185	-4	15228
APR-2024	7648	702	17	20	197	167	32	15274
MAY-2024	7669	700	12	16	191	172	21	15311
JUN-2024	7682	714	5	24	172	176	13	15354
JUL-2024	7699	705	15	10	184	160	17	15387
AUG-2024	7694	715	12	16	163	163	-5	15420
SEP-2024	7689	715	9	7	182	180	-5	15449
OCT-2024	7726	703	8	17	200	166	37	15491

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2023	721	6371	445	44	7581	9.51%	84.04%	5.87%	0.58%	100.00%
FEB-2023	735	6318	429	39	7521	9.77%	84.00%	5.70%	0.52%	100.00%
MAR-2023	750	6312	445	41	7548	9.94%	83.62%	5.90%	0.54%	100.00%
APR-2023	765	6307	440	41	7553	10.13%	83.50%	5.83%	0.54%	100.00%
MAY-2023	802	6314	435	41	7592	10.56%	83.17%	5.73%	0.54%	100.00%
JUN-2023	821	6299	438	41	7599	10.80%	82.89%	5.76%	0.54%	100.00%
JUL-2023	844	6253	440	40	7577	11.14%	82.53%	5.81%	0.53%	100.00%
AUG-2023	866	6240	448	46	7600	11.39%	82.11%	5.89%	0.61%	100.00%
SEP-2023	881	6250	432	46	7609	11.58%	82.14%	5.68%	0.60%	100.00%
OCT-2023	899	6237	433	41	7610	11.81%	81.96%	5.69%	0.54%	100.00%
NOV-2023	920	6210	441	41	7612	12.09%	81.58%	5.79%	0.54%	100.00%
DEC-2023	938	6191	434	40	7603	12.34%	81.43%	5.71%	0.53%	100.00%
JAN-2024	954	6215	432	42	7643	12.48%	81.32%	5.65%	0.55%	100.00%
FEB-2024	974	6198	436	39	7647	12.74%	81.05%	5.70%	0.51%	100.00%
MAR-2024	993	6159	440	44	7636	13.00%	80.66%	5.76%	0.58%	100.00%
APR-2024	1003	6185	437	46	7671	13.08%	80.63%	5.70%	0.60%	100.00%
MAY-2024	1026	6190	434	39	7689	13.34%	80.50%	5.64%	0.51%	100.00%
JUN-2024	1035	6184	429	42	7690	13.46%	80.42%	5.58%	0.55%	100.00%
JUL-2024	1062	6186	434	37	7719	13.76%	80.14%	5.62%	0.48%	100.00%
AUG-2024	1083	6162	431	39	7715	14.04%	79.87%	5.59%	0.51%	100.00%
SEP-2024	1126	6115	426	43	7710	14.60%	79.31%	5.53%	0.56%	100.00%
OCT-2024	1171	6107	428	40	7746	15.12%	78.84%	5.53%	0.52%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2023	6 17%	2971 40%	1 3%	2147 29%	1 3%	16 0%	23 66%	3491 47%	8 23%	1095 15%	29 83%	4465 60%
FEB-2023	3 13%	2944 40%	1 4%	2097 28%	0 0%	17 0%	18 75%	3502 47%	3 13%	1065 14%	21 88%	4446 60%
MAR-2023	2 6%	2936 40%	2 6%	2071 28%	0 0%	15 0%	27 79%	3551 48%	5 15%	1051 14%	32 94%	4476 60%
APR-2023	3 10%	2948 40%	1 3%	2067 28%	0 0%	15 0%	24 83%	3550 48%	3 10%	1030 14%	26 90%	4469 60%
MAY-2023	10 24%	2940 39%	4 10%	2043 27%	1 2%	16 0%	30 71%	3598 48%	3 7%	1040 14%	32 76%	4513 61%
JUN-2023	4 12%	2934 39%	1 3%	2008 27%	0 0%	14 0%	26 76%	3655 49%	4 12%	1002 13%	30 88%	4533 61%
JUL-2023	5 16%	2917 39%	1 3%	1966 26%	0 0%	14 0%	25 81%	3678 49%	2 6%	985 13%	26 84%	4530 61%
AUG-2023	4 9%	2909 39%	1 2%	1935 26%	0 0%	14 0%	34 76%	3717 50%	9 20%	969 13%	41 91%	4561 61%
SEP-2023	2 10%	2902 39%	1 5%	1910 26%	0 0%	13 0%	15 75%	3746 50%	3 15%	954 13%	18 90%	4578 61%
OCT-2023	2 6%	2904 39%	1 3%	1895 25%	0 0%	14 0%	23 74%	3766 50%	6 19%	935 13%	29 94%	4573 61%
NOV-2023	1 3%	2891 39%	0 0%	1866 25%	0 0%	15 0%	27 77%	3783 51%	7 20%	918 12%	34 97%	4585 61%
DEC-2023	6 18%	2874 39%	4 12%	1831 25%	0 0%	13 0%	25 76%	3820 51%	3 9%	895 12%	27 82%	4595 62%
JAN-2024	9 29%	2881 38%	8 26%	1831 24%	0 0%	13 0%	21 68%	3867 52%	2 6%	890 12%	22 71%	4634 62%
FEB-2024	7 22%	2868 38%	4 13%	1795 24%	0 0%	13 0%	22 69%	3896 52%	3 9%	864 12%	25 78%	4641 62%
MAR-2024	2 6%	2845 38%	0 0%	1759 23%	0 0%	13 0%	30 86%	3927 52%	3 9%	844 11%	33 94%	4656 62%
APR-2024	10 22%	2844 38%	5 11%	1742 23%	0 0%	13 0%	34 74%	3969 53%	3 7%	843 11%	36 78%	4691 62%
MAY-2024	4 11%	2822 37%	1 3%	1706 23%	0 0%	12 0%	31 84%	4020 53%	2 5%	832 11%	33 89%	4736 63%
JUN-2024	2 5%	2817 37%	2 5%	1691 22%	0 0%	13 0%	37 86%	4050 54%	4 9%	801 11%	41 95%	4741 63%
JUL-2024	4 13%	2812 37%	1 3%	1667 22%	0 0%	13 0%	24 75%	4079 54%	4 13%	800 11%	28 88%	4765 63%
AUG-2024	2 6%	2796 37%	0 0%	1633 22%	0 0%	13 0%	29 88%	4103 54%	3 9%	783 10%	31 94%	4778 63%
SEP-2024	4 14%	2799 37%	0 0%	1602 21%	0 0%	13 0%	22 76%	4122 54%	4 14%	772 10%	25 86%	4781 63%
OCT-2024	2 5%	2792 37%	1 2%	1558 21%	0 0%	13 0%	39 93%	4181 55%	2 5%	759 10%	40 95%	4826 64%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	atazanavir		darunavir		lopinavir		ritonavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2023	0 0%	339 25%	1 100%	993 72%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
FEB-2023	0 0%	321 24%	0 0%	953 73%	0 0%	43 3%	0 0%	1 0%	0 0%	1 0%
MAR-2023	0 0%	317 24%	1 100%	952 73%	0 0%	42 3%	0 0%	1 0%	0 0%	1 0%
APR-2023	0 0%	305 23%	1 100%	957 74%	0 0%	41 3%	0 0%	1 0%	0 0%	1 0%
MAY-2023	0 0%	303 23%	2 100%	951 74%	0 0%	39 3%	0 0%	1 0%	0 0%	1 0%
JUN-2023	0 0%	294 23%	0 0%	936 74%	0 0%	39 3%	0 0%	1 0%	0 0%	1 0%
JUL-2023	0 0%	283 23%	3 100%	927 74%	0 0%	38 3%	0 0%	1 0%	0 0%	1 0%
AUG-2023	0 0%	276 23%	3 100%	914 75%	0 0%	36 3%	0 0%	0 0%	0 0%	0 0%
SEP-2023	0 0%	271 22%	0 0%	909 75%	0 0%	35 3%	0 0%	0 0%	0 0%	0 0%
OCT-2023	1 50%	273 23%	1 50%	893 75%	0 0%	35 3%	0 0%	0 0%	0 0%	0 0%
NOV-2023	1 33%	260 22%	2 67%	890 75%	0 0%	35 3%	0 0%	0 0%	0 0%	0 0%
DEC-2023	0 0%	248 21%	1 100%	876 76%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%
JAN-2024	0 0%	241 21%	3 100%	866 76%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%
FEB-2024	0 0%	229 21%	0 0%	852 77%	0 0%	31 3%	0 0%	0 0%	0 0%	0 0%
MAR-2024	0 0%	225 21%	1 100%	840 77%	0 0%	30 3%	0 0%	0 0%	0 0%	0 0%
APR-2024	0 0%	224 21%	3 100%	835 77%	0 0%	31 3%	0 0%	0 0%	0 0%	0 0%
MAY-2024	0 0%	221 20%	1 100%	828 77%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%
JUN-2024	1 50%	214 20%	1 50%	813 77%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%
JUL-2024	0 0%	216 21%	0 0%	805 77%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%
AUG-2024	0 0%	208 20%	0 0%	785 77%	0 0%	31 3%	0 0%	0 0%	0 0%	0 0%
SEP-2024	0 0%	203 20%	1 100%	775 77%	0 0%	28 3%	0 0%	0 0%	0 0%	0 0%
OCT-2024	0 0%	197 20%	2 100%	758 77%	0 0%	28 3%	0 0%	0 0%	0 0%	0 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2023	3 43%	192 19%	4 57%	247 25%	0 0%	107 11%	0 0%	255 26%	0 0%	191 19%
FEB-2023	0 0%	202 20%	0 0%	250 25%	0 0%	98 10%	0 0%	249 25%	0 0%	190 19%
MAR-2023	0 0%	209 21%	0 0%	242 25%	0 0%	101 10%	0 0%	246 25%	0 0%	186 19%
APR-2023	1 50%	215 22%	1 50%	232 24%	0 0%	96 10%	0 0%	245 25%	0 0%	187 19%
MAY-2023	1 33%	223 23%	0 0%	232 24%	0 0%	98 10%	0 0%	239 24%	2 67%	187 19%
JUN-2023	0 0%	224 23%	3 75%	228 24%	0 0%	96 10%	0 0%	230 24%	1 25%	180 19%
JUL-2023	0 0%	235 25%	1 100%	222 23%	0 0%	94 10%	0 0%	225 24%	0 0%	178 19%
AUG-2023	0 0%	238 25%	2 100%	222 23%	0 0%	91 10%	0 0%	223 23%	0 0%	182 19%
SEP-2023	0 0%	236 25%	0 0%	218 23%	0 0%	88 9%	1 100%	220 23%	0 0%	177 19%
OCT-2023	0 0%	238 26%	2 100%	216 23%	0 0%	89 10%	0 0%	220 24%	0 0%	173 19%
NOV-2023	0 0%	242 26%	0 0%	209 23%	1 50%	88 9%	0 0%	219 24%	1 50%	173 19%
DEC-2023	1 50%	250 27%	0 0%	205 22%	0 0%	87 9%	0 0%	213 23%	1 50%	176 19%
JAN-2024	0 0%	250 27%	0 0%	200 22%	0 0%	83 9%	0 0%	208 23%	2 100%	181 20%
FEB-2024	0 0%	257 28%	0 0%	192 21%	0 0%	82 9%	0 0%	207 23%	0 0%	182 20%
MAR-2024	0 0%	260 28%	1 100%	190 21%	0 0%	80 9%	0 0%	205 22%	0 0%	181 20%
APR-2024	0 0%	261 29%	0 0%	190 21%	0 0%	82 9%	0 0%	203 22%	0 0%	180 20%
MAY-2024	0 0%	262 29%	0 0%	186 21%	0 0%	80 9%	0 0%	205 23%	0 0%	175 19%
JUN-2024	0 0%	262 29%	0 0%	182 20%	0 0%	79 9%	0 0%	198 22%	0 0%	172 19%
JUL-2024	0 0%	270 30%	0 0%	176 20%	0 0%	78 9%	0 0%	194 22%	1 100%	172 19%
AUG-2024	0 0%	272 31%	0 0%	174 20%	0 0%	78 9%	0 0%	187 21%	0 0%	171 19%
SEP-2024	0 0%	275 31%	2 100%	172 19%	0 0%	77 9%	0 0%	185 21%	0 0%	179 20%
OCT-2024	0 0%	283 32%	0 0%	168 19%	0 0%	74 8%	0 0%	177 20%	0 0%	175 20%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS



**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	bictegravir		cabotegravir		dolutegravir		elvitegravir		fostemsavir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2023	23 82%	3016 50%	0 0%	0 0%	5 18%	2492 41%	0 0%	269 4%	0 0%	2 0%	0 0%	21 0%	0 0%	302 5%
FEB-2023	18 75%	3040 50%	0 0%	0 0%	6 25%	2476 41%	0 0%	255 4%	0 0%	2 0%	0 0%	21 0%	0 0%	288 5%
MAR-2023	25 74%	3084 51%	0 0%	0 0%	5 15%	2482 41%	2 6%	259 4%	0 0%	2 0%	0 0%	20 0%	2 6%	291 5%
APR-2023	22 81%	3084 50%	0 0%	0 0%	4 15%	2498 41%	1 4%	258 4%	0 0%	2 0%	0 0%	18 0%	0 0%	274 4%
MAY-2023	28 67%	3138 51%	1 2%	3 0%	12 29%	2504 41%	1 2%	250 4%	0 0%	2 0%	0 0%	18 0%	0 0%	278 5%
JUN-2023	26 81%	3197 51%	0 0%	5 0%	6 19%	2509 40%	0 0%	248 4%	0 0%	2 0%	0 0%	18 0%	0 0%	267 4%
JUL-2023	25 83%	3218 52%	0 0%	5 0%	5 17%	2499 40%	0 0%	247 4%	0 0%	2 0%	0 0%	18 0%	0 0%	256 4%
AUG-2023	33 79%	3258 52%	0 0%	7 0%	6 14%	2495 40%	1 2%	245 4%	0 0%	2 0%	0 0%	18 0%	2 5%	253 4%
SEP-2023	15 79%	3289 52%	0 0%	8 0%	4 21%	2500 40%	0 0%	238 4%	0 0%	2 0%	0 0%	18 0%	0 0%	249 4%
OCT-2023	22 76%	3298 52%	0 0%	7 0%	7 24%	2523 40%	0 0%	241 4%	0 0%	2 0%	0 0%	18 0%	0 0%	248 4%
NOV-2023	27 82%	3327 53%	0 0%	9 0%	6 18%	2518 40%	0 0%	233 4%	0 0%	1 0%	0 0%	17 0%	0 0%	244 4%
DEC-2023	24 77%	3365 53%	0 0%	13 0%	7 23%	2506 40%	0 0%	226 4%	0 0%	2 0%	0 0%	16 0%	0 0%	237 4%
JAN-2024	20 65%	3419 53%	1 3%	16 0%	10 32%	2520 39%	0 0%	224 4%	0 0%	2 0%	0 0%	18 0%	0 0%	234 4%
FEB-2024	21 66%	3453 54%	0 0%	15 0%	10 31%	2516 39%	0 0%	219 3%	0 0%	2 0%	0 0%	18 0%	1 3%	231 4%
MAR-2024	30 88%	3498 54%	0 0%	17 0%	4 12%	2500 39%	0 0%	220 3%	0 0%	3 0%	0 0%	17 0%	0 0%	225 3%
APR-2024	34 76%	3546 55%	0 0%	17 0%	11 24%	2497 38%	0 0%	216 3%	0 0%	2 0%	0 0%	18 0%	0 0%	225 3%
MAY-2024	29 78%	3588 55%	0 0%	19 0%	8 22%	2488 38%	0 0%	213 3%	0 0%	2 0%	0 0%	15 0%	0 0%	222 3%
JUN-2024	37 88%	3617 55%	0 0%	21 0%	5 12%	2488 38%	0 0%	207 3%	0 0%	2 0%	0 0%	17 0%	0 0%	218 3%
JUL-2024	22 67%	3652 55%	1 3%	25 0%	6 18%	2500 38%	4 12%	212 3%	0 0%	2 0%	0 0%	17 0%	0 0%	213 3%
AUG-2024	29 88%	3689 56%	0 0%	26 0%	4 12%	2487 38%	0 0%	204 3%	0 0%	2 0%	0 0%	17 0%	0 0%	207 3%
SEP-2024	21 78%	3709 56%	0 0%	32 0%	5 19%	2498 38%	1 4%	200 3%	0 0%	2 0%	0 0%	16 0%	0 0%	206 3%
OCT-2024	39 93%	3769 56%	0 0%	34 1%	3 7%	2511 37%	0 0%	199 3%	0 0%	2 0%	0 0%	15 0%	0 0%	201 3%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Fostemsavir not currently on BC-CfE Formulary





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		3 drugs from 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2023	750	9.89	665	8.77	4728	62.37	718	9.47	649	8.56	71	0.94
FEB-2023	715	9.51	665	8.84	4712	62.65	733	9.75	626	8.32	70	0.93
MAR-2023	699	9.26	653	8.65	4735	62.73	748	9.91	644	8.53	69	0.91
APR-2023	704	9.32	653	8.65	4736	62.70	762	10.09	634	8.39	64	0.85
MAY-2023	706	9.30	644	8.48	4752	62.59	800	10.54	627	8.26	63	0.83
JUN-2023	675	8.88	625	8.22	4788	63.01	819	10.78	627	8.25	65	0.86
JUL-2023	662	8.74	626	8.26	4758	62.80	842	11.11	628	8.29	61	0.81
AUG-2023	643	8.46	621	8.17	4773	62.80	864	11.37	632	8.32	67	0.88
SEP-2023	639	8.40	616	8.10	4793	62.99	879	11.55	617	8.11	65	0.85
OCT-2023	615	8.08	611	8.03	4808	63.18	897	11.79	618	8.12	61	0.80
NOV-2023	611	8.03	599	7.87	4799	63.05	918	12.06	624	8.20	61	0.80
DEC-2023	593	7.80	596	7.84	4808	63.24	936	12.31	614	8.08	56	0.74
JAN-2024	583	7.63	585	7.65	4857	63.55	952	12.46	609	7.97	57	0.75
FEB-2024	564	7.38	586	7.66	4861	63.57	971	12.70	609	7.96	56	0.73
MAR-2024	543	7.11	580	7.60	4846	63.46	991	12.98	618	8.09	58	0.76
APR-2024	538	7.01	570	7.43	4885	63.68	1000	13.04	621	8.10	57	0.74
MAY-2024	536	6.97	566	7.36	4904	63.78	1023	13.30	607	7.89	53	0.69
JUN-2024	526	6.84	556	7.23	4913	63.89	1033	13.43	606	7.88	56	0.73
JUL-2024	520	6.74	541	7.01	4940	64.00	1060	13.73	605	7.84	53	0.69
AUG-2024	506	6.56	537	6.96	4939	64.02	1081	14.01	602	7.80	50	0.65
SEP-2024	486	6.30	530	6.87	4922	63.84	1124	14.58	596	7.73	52	0.67
OCT-2024	470	6.07	512	6.61	4953	63.94	1168	15.08	595	7.68	48	0.62

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month



**2.11 Baseline CD4 for Antiretroviral First Starts**

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2023	10	2	2	2	2	2	285
FEB-2023	11	2	2	3	1	3	253
MAR-2023	21	0	0	4	3	11	530
APR-2023	11	1	3	1	1	4	325
MAY-2023	15	2	1	2	5	2	374
JUN-2023	17	2	4	3	2	6	340
JUL-2023	11	1	2	3	2	3	260
AUG-2023	13	2	1	4	2	2	255
SEP-2023	5	1	1	0	0	3	616
OCT-2023	10	0	1	3	2	3	390
NOV-2023	9	1	1	0	2	4	575
DEC-2023	13	1	0	3	0	8	592
JAN-2024	11	2	2	2	1	3	287
FEB-2024	11	1	2	4	2	1	281
MAR-2024	14	3	2	1	1	5	345
APR-2024	20	0	4	6	1	9	364
MAY-2024	16	2	3	3	1	6	320
JUN-2024	24	1	1	10	4	8	360
JUL-2024	10	0	1	3	3	2	374
AUG-2024	16	3	2	4	3	4	330
SEP-2024	7	0	1	4	1	1	280
OCT-2024	17	6	0	4	3	4	298

Definitions:**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)**Baseline CD4** is defined as most recent CD4 test before ARV start



2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2023	12447	3802
FEB-2023	12435	3787
MAR-2023	12442	3786
APR-2023	12417	3752
MAY-2023	12425	3730
JUN-2023	12398	3692
JUL-2023	12425	3715
AUG-2023	12422	3697
SEP-2023	12409	3685
OCT-2023	12393	3661
NOV-2023	12379	3648
DEC-2023	12400	3656
JAN-2024	12410	3664
FEB-2024	12423	3671
MAR-2024	12455	3686
APR-2024	12480	3691
MAY-2024	12488	3688
JUN-2024	12498	3668
JUL-2024	12495	3663
AUG-2024	12482	3643
SEP-2024	12503	3663
OCT-2024	12510	3647

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month






HIV/AIDS Drug Treatment Program

Monthly Report


3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7746

Oct-2024

BY HEALTH SERVICES DELIVERY AREA




BY HEALTH AUTHORITY






3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Oct-2024

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Oct-2024

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Oct-2024

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Oct-2024

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Oct-2024

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	5	5	5
	35-49	12	12	6
	50+	31	48	18
	Total HSDA:	48	65	29
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	74	105	52
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	477	642	355
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	237	330	178
Total HA:		836	1142	614

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		836	1142	614

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	164	228	114
Male	672	914	500

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	614	56	660	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	26	11
	5 years or more	13	10
	<5 years	9	8
	Total HSDA:	48	29
KOOTENAY BOUNDARY	10 years or more	54	37
	5 years or more	11	8
	<5 years	9	7
	Total HSDA:	74	52
OKANAGAN	10 years or more	305	225
	5 years or more	83	59
	<5 years	89	71
	Total HSDA:	477	355
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	144	110
	5 years or more	42	28
	<5 years	51	40
	Total HSDA:	237	178
Total HA:		836	614

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	529	383
5 years or more	149	105
<5 years	158	126
Total HA:	836	614

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribers in BC-CfE Registries INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
EAST KOOTENAY	54	101	13	31
KOOTENAY BOUNDARY	76	139	19	42
OKANAGAN	243	1099	52	326
THOMPSON/CARIBOO/SHUSWAP	152	584	29	139
Total:	525	1923	113	538

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	130

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	5
	20-34	50	51	38
	35-49	109	113	71
	50+	279	391	209
	Total HSDA:	444	561	323
FRASER NORTH	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	1189	1613	905
FRASER SOUTH	0-19	7	7	7
	20-34	140	145	122
	35-49	316	344	259
	50+	654	1005	519
	Total HSDA:	1117	1501	907
Total HA:		2750	3675	2135

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	17	17	16
	20-34	325	333	272
	35-49	783	840	601
	50+	1625	2485	1246
Total HA:		2750	3675	2135

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	654	842	505
Male	2096	2833	1630

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	2135	53	660	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	287	212
	5 years or more	77	46
	<5 years	80	65
	Total HSDA:	444	323
FRASER NORTH	10 years or more	751	547
	5 years or more	215	167
	<5 years	223	191
	Total HSDA:	1189	905
FRASER SOUTH	10 years or more	672	523
	5 years or more	197	156
	<5 years	248	228
	Total HSDA:	1117	907
Total HA:		2750	2135

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1710	1282
	5 years or more	489	369
	<5 years	551	484
Total HA:		2750	2135

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation



4.6 Distribution of ARV Prescribers in BC-CfE Registries FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
FRASER EAST	154	560	33	65
FRASER NORTH	267	1658	33	241
FRASER SOUTH	236	1917	47	540
Total:	657	4135	113	846

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
FRASER EAST	215
FRASER NORTH	740
FRASER SOUTH	482
Total:	1437

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth VANCOUVER COASTAL Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	371	550	286
RICHMOND	20-34	28	29	21
	35-49	59	60	46
	50+	126	183	101
	Total HSDA:	213	272	168
VANCOUVER	0-19	8	8	5
	20-34	386	399	291
	35-49	1211	1353	823
	50+	3002	5476	2098
	Total HSDA:	4607	7236	3217
Total HA:		5191	8058	3671

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	12	12	9
	20-34	443	457	328
	35-49	1348	1497	927
	50+	3388	6092	2407
Total HA:		5191	8058	3671

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	586	978	445
Male	4605	7080	3226

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3671	56	660	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	263	202
	5 years or more	51	39
	<5 years	57	45
	Total HSDA:	371	286
RICHMOND	10 years or more	123	95
	5 years or more	34	25
	<5 years	56	48
	Total HSDA:	213	168
VANCOUVER	10 years or more	3318	2260
	5 years or more	696	489
	<5 years	593	468
	Total HSDA:	4607	3217
Total HA:		5191	3671

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	3704	2557
	5 years or more	781	553
	<5 years	706	561
Total HA:		5191	3671

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation



4.9 Distribution of ARV Prescribers in BC-CfE Registries VANCOUVER COASTAL Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH SHORE/COAST GARIBALDI	198	575	39	61
RICHMOND	49	334	10	108
VANCOUVER	706	11959	209	5439
Total:	953	12868	258	5608

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	62

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth VANCOUVER ISLAND Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	366	539	294
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	143	198	118
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	854	1222	643
Total HA:		1363	1959	1055

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	6
	20-34	104	112	68
	35-49	311	345	244
	50+	942	1496	737
Total HA:		1363	1959	1055

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	221	325	170
Male	1142	1634	885

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1055	57	610	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	243	199
	5 years or more	69	48
	<5 years	54	47
	Total HSDA:	366	294
NORTH VANCOUVER ISLAND	10 years or more	105	88
	5 years or more	24	16
	<5 years	14	14
	Total HSDA:	143	118
SOUTH VANCOUVER ISLAND	10 years or more	542	402
	5 years or more	155	113
	<5 years	157	128
	Total HSDA:	854	643
Total HA:		1363	1055

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	890	689
	5 years or more	248	177
	<5 years	225	189
Total HA:		1363	1055

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation



4.12 Distribution of ARV Prescribers in BC-CfE Registries VANCOUVER ISLAND Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
CENTRAL VANCOUVER ISLAND	212	958	68	202
NORTH VANCOUVER ISLAND	158	366	31	65
SOUTH VANCOUVER ISLAND	236	2050	43	609
Total:	606	3374	142	876

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
CENTRAL VANCOUVER ISLAND	83
NORTH VANCOUVER ISLAND	49
SOUTH VANCOUVER ISLAND	128
Total:	260

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	8	8	5
	35-49	19	22	12
	50+	32	42	19
	Total HSDA:	59	72	36
NORTH WEST	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	83	131	63
NORTHERN INTERIOR	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	205	313	156
Total HA:		347	516	255

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		347	516	255

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	116	179	82
Male	231	337	173

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	255	53	570	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)



4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration NORTHERN Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	31	14
	5 years or more	9	5
	<5 years	19	17
	Total HSDA:	59	36
NORTH WEST	10 years or more	57	42
	5 years or more	12	8
	<5 years	14	13
	Total HSDA:	83	63
NORTHERN INTERIOR	10 years or more	125	99
	5 years or more	52	35
	<5 years	28	22
	Total HSDA:	205	156
Total HA:		347	255

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	213	155
	5 years or more	73	48
	<5 years	61	52
Total HA:		347	255

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation



4.15 Distribution of ARV Prescribers in BC-CfE Registries NORTHERN Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH EAST	39	51	3	*
NORTH WEST	90	171	14	*
NORTHERN INTERIOR	129	523	25	*
Total:	258	745	42	233

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH EAST	7
NORTH WEST	28
NORTHERN INTERIOR	19
Total:	54

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at Birth

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	12	*
	KOOTENAY BOUNDARY	6	9	*
	OKANAGAN	30	51	*
	THOMPSON/CARIBOO/SHUSWAP	28	59	*
	Total HA:	70	131	47
FRASER	FRASER EAST	35	52	28
	FRASER NORTH	49	93	39
	FRASER SOUTH	80	119	59
	Total HA:	164	264	126
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	30	57	*
	RICHMOND	5	11	*
	VANCOUVER	427	913	*
	Total HA:	462	981	357
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	49	85	39
	NORTH VANCOUVER ISLAND	16	31	13
	SOUTH VANCOUVER ISLAND	49	98	36
	Total HA:	114	214	88
NORTHERN	NORTH EAST	13	17	9
	NORTH WEST	39	75	30
	NORTHERN INTERIOR	72	124	59
	Total HA:	124	216	98
Total:		934	1806	716

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	598	1164	451
Female	336	642	265

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	716	54	560	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir: a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Antiretroviral: a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla: the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose of RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

Cabenuva: the ViiV Healthcare trade name for an injectable formulation containing CABOTEGRAVIR and RILPIVIRINE.

Cabotegravir: an INTEGRASE INHIBITOR.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer ("booster") given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Complera: the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Descovy: the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.





Didanosine (Videx): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir: an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine: a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fostemsavir: an ATTACHMENT INHIBITOR from ViiV Healthcare. Fostemsavir is a PRODRUG of TEMSAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa: the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine: a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.





MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

N(t)RTI: a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Odefsey: the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix: the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.





Raltegravir (Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure ("booster").

Stavudine (Zerit): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq: the ViiV Healthcare's trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir: the ViiV Healthcare's trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada: the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.